Hagop Youssoufian: Encelimab with or without dostarlimab in advanced/metastatic solid tumors
Hagop Youssoufian, Founder and Principal at Youssoufian Consulting, shared a post on LinkedIn about a paper he co-authored with colleagues published in BJC Reports:
“Happy to share the publication of our paper: ‘CITRINO: Phase 1 Dose Escalation Study of Anti-LAG-3 Antibody Encelimab Alone or in Combination with Anti-PD-1 Dostarlimab in Patients with Advanced/Metastatic Solid Tumors.’
A bit of a spoiler alert: this isn’t a breakthrough or a game-changer. In fact, it’s not even a positive study. But it represents a valiant effort to tackle an incredibly challenging situation for patients – led by an exceptional team of investigators under the leadership of the great Dr. Randy Hecht.
I had the privilege of serving as study lead, first at Tesaro and later at GSK. From the outset, we knew we were on a steep learning curve with LAG-3: Do we have the right antibody? The right biomarkers? This type of uncertainty is not uncommon in drug development – it often feels like building a complex airplane mid-flight.
Yet, even negative data have value, especially when dealing with stubborn drug targets like LAG-3. That’s why I’m deeply grateful to GSK for upholding the highest standards in scientific transparency and ensuring that these findings are shared with the broader research community.”
Authors: Randolph Hecht, Jean-Marie Michot, David Bajor, Hagop Youssoufian, Ivan Diaz-Padilla, Susanna Ulahannan et al.
M0re posts featuring Hagop Youssoufian.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023